Compare Global X FTSE Southeast Asia ETF (ASEA) vs HCA Health Inc (HCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs HCA Health Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while HCA Health Inc trades at $404.6 (market cap $90.20B). The key difference: HCA Health Inc pays a 0.77% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, HCA Health Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | HCA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $545.13 |
52-Week Low | $16.31 | $334.32 |
Market Cap | — | $90.20B |
Enterprise Value | — | $139.10B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
HCA Healthcare trades at $406.59, down 0.59% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $7.37. Revenue growth is robust, reaching $75.60 billion in 2025, while valuation metrics like a P/E of 14.01 and EV/EBITDA of 8.88 suggest relative attractiveness. Recent news highlights capacity expansion and gene therapy advancements.
The outlook for HCA remains positive, supported by earnings momentum and strategic investments, but risks include high debt levels and regulatory pressures. Analyst consensus is bullish with a $486.10 price target, indicating ~20% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
